The Earnings Season: Complementary Research on Rosetta Genomics, Alder Biopharmaceuticals, TASER International, GrafTech, and Rockwell Automation
NEW YORK, May 6, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Rosetta Genomics, Ltd. (NASDAQ: ROSG), Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), TASER International Inc. (NASDAQ: TASR), GrafTech International Ltd. (NYSE: GTI), and Rockwell Automation Inc. (NYSE: ROK). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
ROSG Research Report: ( http://get.analystsreview.com/pdf/?c=Rosetta%20Genomics&d=06-May-2015&s=ROSG ),
ALDR Research Report: ( http://get.analystsreview.com/pdf/?c=Alder%20Biopharmaceuticals&d=06-May-2015&s=ALDR ),
TASR Research Report: ( http://get.analystsreview.com/pdf/?c=TASER%20International&d=06-May-2015&s=TASR ),
GTI Research Report: ( http://get.analystsreview.com/pdf/?c=GrafTech%20International&d=06-May-2015&s=GTI ),
ROK Research Report: ( http://get.analystsreview.com/pdf/?c=Rockwell%20Automation&d=06-May-2015&s=ROK ).
============
--
Analyst Update: Patent, Financial Results, Scheduled Earnings
U.S. stocks tumbled on Tuesday as investors turned nervous amid a sharp increase in the US trade deficit gap. The NASDAQ Composite slipped 1.55%, to close at 4,939.33, the S&P 500 declined by 1.18%, to 2,089.46, and the Dow Jones Industrial Average end the session at 17,928.20, down 0.79%. European stocks closed lower on Tuesday amid increasing uncertainty over Greece's future. Germany's DAX 30 fell 2.51%, France's CAC 40 declined 2.12%, and the London's FTSE 100 closed 0.84% lower on Tuesday. Meanwhile, Asian markets drifted on Tuesday as the Reserve Bank of Australia cut interest rates and factory output in China stumbled. The Shanghai Composite; Australia's S&P ASX and Hong Kong's Hang Seng index all fell on Tuesday.
Rosetta Genomics (Rosetta) on April 29, 2015 announced that the European Patent Office (EPO) has upheld the validity of its European Patent No. 2126078, following the oral proceedings in the Opposition Proceedings against Rosetta's patent held on April 23, 2015 in Munich, Germany. Rosetta got the patent grant in April 2012, and ever since two opposition requests were filed by anonymous parties.
Alder BioPharmaceuticals (Alder), clinical-stage Biopharmaceutical Company, on April 30 2015 announced that the Company will report its first quarter 2015 financial and operating results after the close of U.S. financial markets on Thursday, May 7, 2015. Alder management will host a conference call and live audio webcast at 5 p.m. EDT on the same day.
TASER International (TASER) on April 30, 2015 announced financial results for the first quarter 2015 (period ended March 31, 2015). Net sales were $44.8 million in Q1 2015, up 23.7% YoY, primarily driven by increased TASER X26P and TASER X2 Smart Weapon sales.
GrafTech International (GrafTech) reported its first quarter 2015 (period ended March 31, 2015) results on April 29, 2015. The Company saw a net sale of $207 million, down 26% YoY, primarily attributed to lower shipment volumes and pricing. GrafTech reported a net loss of $56 million, or $0.41 loss per diluted share in Q1 2015, compared to reported net loss of $12 million, or $0.08 loss per diluted share, in the same period year ago.
Rockwell Automation (Rockwell) on April 30, 2015 reported fiscal 2015-second quarter results. Total sales were $1,550.8 million in Q2 FY 2015, down 3.1% YoY. The Company reported a net income of $206.0 million or $1.51 per share in Q2 FY 2015, compared to $180.3 million or $1.28 per share in the same quarter year ago. Meanwhile, adjusted EPS was $1.59 in Q2 FY 2015, compared to $1.35 in Q2 FY 2014.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article